Benign Prostatic Hyperplasia

New GnRH Antagonist Shows Promise for LUTS

ANAHEIM, Calif.—Ozarelix, a GnRH antagonist given intramuscularly, is well tolerated and has significant and clinically meaningful efficacy in the treatment of lower urinary tract symptoms (LUTS) secondary to BPH, a study shows.

Laser Meets the BPH Gold Standard

For 30 years, lasers have been evolving for the treatment of urologic conditions. Investigators focused on lasers for BPH to achieve results similar to transurethral resection of the prostate (TURP) without the bleeding, fluid overload, blood loss, inpatient hospital stays of two to three days, and erectile dysfunction associated with TURP.

PCPs May Miss LUTS Cases

ANAHEIM, Calif.—Moderate to severe lower urinary tract symptoms (LUTS) are present in 42% of men over age 50 who visit their primary-care physician (PCP), according to data presented here at the American Urological Association annual meeting.

Botox Better Than Expected

Botox Better Than Expected

ANAHEIM, Calif.—Just one injection of botulinum toxin type A (Botox) into the prostate may provide relief from BPH-related lower urinary tract symptoms (LUTS) for up to 12 months.

Next post in Commentary